Last reviewed · How we verify
SB17170
At a glance
| Generic name | SB17170 |
|---|---|
| Sponsor | SPARK Biopharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SB17170 Phase 1 Clinical Trial in Solid Tumors (PHASE1)
- SB17170 Phase 2 Trial in IPF Patients (PHASE2)
- A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects (PHASE1)
- SB17170 Phase1 Trial in Healthy Volunteer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB17170 CI brief — competitive landscape report
- SB17170 updates RSS · CI watch RSS
- SPARK Biopharma portfolio CI